DJIA 15,973.84 313.66 2.00%
NASDAQ 4,337.51 70.68 1.66%
S&P 500 1,864.78 35.70 1.95%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

31.27 0.13 (0.42%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

RHHBY $31.27 0.42%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $31.07
Previous Close $31.14
Daily Range $30.92 - $31.37
52-Week Range $30.85 - $38.54
Market Cap $175.8B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.7%)
Volume 797,824
Average Daily Volume 1,398,964
Current FY EPS $1.80





Roche Holding Ltd. (ADR) (RHHBY) Description


News & Commentary Rss Feed

Why Ophthotech Corporation Shares Tumbled 31% in January

The launch of trials in dry age-related macular degeneration failed to spark shares last month.

3 Healthcare Technologies That Are Set to Transform Our Lives Over the Next 10 Years

Learn more about healthcare technologies and trends such as these -- and you will discover some intriguing investment possibilities

Will 2016 Be Celgene Corporation's Best Year Yet?

Celgene outperformed the broader market in 2015, but can the company deliver superior results once more in 2016?

3 Predictions for Celldex Therapeutics, Inc. in 2016

What might be in store in 2016 for this up-and-coming biotech.

Everything You Need to Know About Celgene Summed Up in 5 Slides

Celgene's presentation at the Super Bowl of all healthcare conferences on Monday unearthed plenty of must-know information for investors.

Exelixis, Inc. Nearly Quadrupled in 2015 -- Here's Why

Exelixis stock surged 291% in 2015, and it has these two events to thank for the rapid rise.

Will 2016 Be Inovio Pharmaceuticals, Inc.'s Best Year Yet?

2015 was horrible for this biotech. Here's what could be on tap in the New Year.

These Approved and Developing Drugs Had a Major Impact on Patient Survival in 2015

Four drugs made a huge impact on patient survival in 2015 according to clinical trials, and one of them can be bought over the counter.

A Big Year Could Be on Tap for Puma Biotechnology in 2016

The company is sticking to plans to file for FDA approval of neratinib in the first quarter of 2016.

3 Small-Cap Biotech Stocks With Big News Coming in 2016

Clinical trial results will be coming out next year that could significantly move the shares in these stocks higher or lower.

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $31.27 (0.42%)
Current stock: RHHBY
JNJ $101.82 (0.12%)
Current stock: JNJ
NVS $72.70 (0.69%)
Current stock: NVS
GSK $39.76 (1.56%)
Current stock: GSK